1 - 181 http://localhost:8080/xmlui/handle/123456789/9115 2026-04-15T15:09:28Z 2026-04-15T15:09:28Z Su, Wen-Lin Lin, Chih-Pei Huang, Hui-Ching Wu, Yao-Kuang Yang, Mei-Chen Chiu, Sheg-Kang http://localhost:8080/xmlui/handle/123456789/9177 2024-12-17T05:01:44Z 2022-02-01T00:00:00Z

Title: Clinical application of 222 nm wavelength ultraviolet C irradiation on SARS CoV-2 contaminated environments Authors: Su, Wen-Lin; Lin, Chih-Pei; Huang, Hui-Ching; Wu, Yao-Kuang; Yang, Mei-Chen; Chiu, Sheg-Kang Abstract: Abstract This was a preliminary study on ultraviolet C (UVC) irradiation for SARS-CoV-2- contaminated hospital environments. Forty-eight locations were tested for SARS-CoV-2 using RT-PCR (33.3% contamination rate). After series dosages of 222-nm UVC irradiation, samples from the surfaces were negative at 15 s irradiation at 2 cm length (fluence: 81 mJ/cm2 ).

2022-02-01T00:00:00Z Wu, Pei-Ying Sun, Hsin-Yun Chen, Mao-Yuan Sheng, Wang-Huei Hsieh, Szu-Min Chuang, Yu-Chung http://localhost:8080/xmlui/handle/123456789/9176 2024-12-17T04:50:11Z 2022-02-01T00:00:00Z

Title: Participation in cancer screening among people living with HIV at a university hospital Authors: Wu, Pei-Ying; Sun, Hsin-Yun; Chen, Mao-Yuan; Sheng, Wang-Huei; Hsieh, Szu-Min; Chuang, Yu-Chung Abstract: Abstract Between March and October, 2018, 1248 people living with HIV completed questionnaire interviews for cancer screening, of whom 46.9% (n Z 585) completed free-ofcharge cancer screening. Time constraint (50.1%) was the most common reason provided for refusal to participate in cancer screening. None of the participants were diagnosed with any of the four cancers

2022-02-01T00:00:00Z Liu, Kai-Yuan Chao, Hsiao-Mei Lu, Yen-Jung Su, Ying-Shih Lee, Wen-Sen http://localhost:8080/xmlui/handle/123456789/9175 2024-12-17T04:23:08Z 2022-02-01T00:00:00Z

Title: Cytomegalovirus proctitis in non-human immunodeficiency virus infected patients: A case report and literature review Authors: Liu, Kai-Yuan; Chao, Hsiao-Mei; Lu, Yen-Jung; Su, Ying-Shih; Lee, Wen-Sen Abstract: Abstract Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality in both immunocompetent and immunocompromised patients. CMV is a ubiquitous Herpesviridae virus with a wide spectrum of pathologies in humans. Immunocompetent patients generally develop a benign, self-limited mononucleosis-like syndrome, whereas gastrointestinal tissue-invasive disease is more frequently seen in immunocompromised. The clinical manifestations of CMV colitis or proctitis are demarcated by bloody diarrhea, ulcerations, ulceroinfiltrative changes, and pseudomembranous formation on colonoscopy. Gastrointestinal CMV infections complicated with deep rectal ulcer and fistula formation are rare in patients with systemic lupus erythematosus. Ganciclovir is also the gold standard therapy for CMV colitis or proctitis

2022-02-01T00:00:00Z Asai, Nobuhiro Sakanashi, Daisuke Suematsu, Hiroyuki Kato, Hideo Hagihara, , Mao Shiota, Arufumi http://localhost:8080/xmlui/handle/123456789/9174 2024-12-17T04:11:44Z 2022-02-01T00:00:00Z

Title: To what degree could clinical trials in evidence based medicine reflect reality in the treatment of candidemia? Authors: Asai, Nobuhiro; Sakanashi, Daisuke; Suematsu, Hiroyuki; Kato, Hideo; Hagihara, , Mao; Shiota, Arufumi Abstract: Abstract Introduction: Evidenced based medicine (EBM) is necessary to standardize or treatment for infection since EBM is established based on the results of clinical trials. Entry criteria for clinical trials are very strict, and many patients have difficulties in being enrolled in any clinical trials regarding candidemia. It is questionable if the results of clinical trials reflect the real world of general medicine in this case. Patients and methods: For the purpose of examining how many patients could join any randomized clinical trials for the treatment of candidemia, we reviewed all the candidemia patients in our institute during 2014e2018. The patients were divided into two groups: patients who were eligible for clinical trials (participation possible group), and those who were not (participation impossible group). Exclusion criteria for clinical trials were set based on previous clinical trials. Results: A total of 70 patients was enrolled in this study. The median age was 73 years (range 36e93 years). Of these, 41 patients (59%) were male. As for site of infections, catheter related blood stream infection was most frequently seen in 37 (53%). Seventeen patients (24%) were classified as participation possible group and 53 patients (76%) were participation impossible group. Comparing the two groups, participation possible group patients have much better performance status, have less comorbidities and have longer overall survival times than participation impossible group patients. Conclusion: Only 24% of candidemia patients were eligible for the clinical trials. Thus, we can see that clinical trials might not correctly reflect the real world among candidemia patients.

2022-02-01T00:00:00Z